ArticleCase reports in oncological medicine2025
The Importance of Next-Generation Sequencing in Identifying Immunohistochemically Ambiguous Pediatric Sarcomas.
Article in Case reports in oncological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond COL1A1::PDGFB: Rare fusions and their clinical implications in dermatofibrosarcoma protuberans.World journal of clinical cases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone and soft-tissue sarcomas encompass over 70 histologic subtypes, posing diagnostic challenges due to overlapping characteristics. Molecular analyses, such as fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR), aid in identifying specific genomic alterations but are often limited, particularly when prior histological findings are inconclusive. Next-generation sequencing (NGS) offers high-throughput testing via a targeted sequencing panel, addressing these limitations. This case series highlights the utility of NGS in diagnosing two pediatric patients with immunobiologically ambiguous Ewing sarcoma (ES) and clear cell sarcoma (CCS), emphasizing its role as a powerful tool in solid tumor diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.